Nuvectis (NVCT) Form 3: Director holds 35,150 common shares

Nuvectis Pharma (NVCT) reported an initial Form 3 for a director with an event date of 09/22/2025.

Rhea-AI Filing Summary

Nuvectis Pharma (NVCT) reported an initial Form 3 for a director with an event date of 09/22/2025. The filing lists beneficial ownership of 35,150 shares of common stock (direct), plus 295 shares (indirect) and 120 shares (indirect) held as custodian for a son. Table II shows no derivative securities. The form was signed by Juan Sanchez on 10/31/2025.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Sanchez Juan

Role Director

Type	Security	Shares	Price	Value
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 35,150 shares (Direct); Common Stock — 415 shares (Indirect, As custodian for son)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Nuvectis Pharma (NVCT) file?

A Form 3, the initial statement of beneficial ownership under Section 16.

Who is the reporting person on NVCT’s Form 3?

Juan Sanchez, who signed the form on 10/31/2025.

What is the reporting person’s relationship to NVCT?

The individual is a Director.

How many NVCT shares are owned directly?

The filing reports 35,150 shares of common stock held directly.

What indirect holdings are reported on the Form 3?

Indirect holdings include 295 shares and 120 shares, each held as custodian for a son.

Were any derivative securities reported?

No. Table II shows no derivative securities listed.

What is the event date on the Form 3?

The event date is 09/22/2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/31/2025 - 08:00 AM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Sanchez Juan

(Last) (First) (Middle)

C/O NUVECTIS PHARMA, INC.,

1 BRIDGE PLAZA, SUITE 275

(Street)

FORT LEE NJ 07024

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
09/22/2025

3. Issuer Name and Ticker or Trading Symbol
Nuvectis Pharma, Inc. [ NVCT ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	35,150	D
Common Stock	295	I	As custodian for son
Common Stock	120	I	As custodian for son

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Juan Sanchez	10/31/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.